ImmunoGen IMGN today announced the
presentation of clinical findings with SAR3419 (coltuximab ravtansine)
used in combination with Rituxan® (rituximab) to treat
diffuse large B-cell lymphoma (DLBCL) that previously had been treated
with standard therapies. SAR3419 is a CD19-targeting ADC developed by
ImmunoGen and licensed to Sanofi as part of a broader collaboration
between the companies. These findings were reported at the annual
meeting of the American Society of Hematology (ASH) being held in New
Orleans, LA.
The data presented today are from a Phase II trial assessing the
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in